Free Trial

BioHarvest Sciences (BHST) Competitors

$6.20 +0.01 (+0.16%)
(As of 12/18/2024 05:26 PM ET)

BHST vs. GHRS, AKBA, ESPR, LRMR, CYRX, OLMA, SAGE, CTNM, KMDA, and AQST

Should you be buying BioHarvest Sciences stock or one of its competitors? The main competitors of BioHarvest Sciences include GH Research (GHRS), Akebia Therapeutics (AKBA), Esperion Therapeutics (ESPR), Larimar Therapeutics (LRMR), Cryoport (CYRX), Olema Pharmaceuticals (OLMA), Sage Therapeutics (SAGE), Contineum Therapeutics (CTNM), Kamada (KMDA), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical preparations" industry.

BioHarvest Sciences vs.

BioHarvest Sciences (NASDAQ:BHST) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

GH Research has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -76.65%. BioHarvest Sciences' return on equity of 0.00% beat GH Research's return on equity.

Company Net Margins Return on Equity Return on Assets
BioHarvest Sciences-76.65% N/A -85.16%
GH Research N/A -20.29%-19.49%

In the previous week, BioHarvest Sciences had 3 more articles in the media than GH Research. MarketBeat recorded 3 mentions for BioHarvest Sciences and 0 mentions for GH Research. GH Research's average media sentiment score of 1.63 beat BioHarvest Sciences' score of 0.60 indicating that GH Research is being referred to more favorably in the news media.

Company Overall Sentiment
BioHarvest Sciences Positive
GH Research Very Positive

GH Research received 22 more outperform votes than BioHarvest Sciences when rated by MarketBeat users. However, 100.00% of users gave BioHarvest Sciences an outperform vote while only 72.73% of users gave GH Research an outperform vote.

CompanyUnderperformOutperform
BioHarvest SciencesOutperform Votes
2
100.00%
Underperform Votes
No Votes
GH ResearchOutperform Votes
24
72.73%
Underperform Votes
9
27.27%

BioHarvest Sciences has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioHarvest Sciences$22.43M4.54-$12.56M-$1.25-4.96
GH ResearchN/AN/A-$35.59M-$0.79-9.37

BioHarvest Sciences currently has a consensus target price of $13.00, suggesting a potential upside of 109.68%. GH Research has a consensus target price of $35.67, suggesting a potential upside of 381.98%. Given GH Research's higher probable upside, analysts clearly believe GH Research is more favorable than BioHarvest Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioHarvest Sciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
GH Research
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

56.9% of GH Research shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

GH Research beats BioHarvest Sciences on 9 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BHST vs. The Competition

MetricBioHarvest SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$101.84M$6.71B$5.03B$8.97B
Dividend YieldN/A3.07%4.81%4.06%
P/E Ratio-4.9610.45133.1816.92
Price / Sales4.54187.361,119.91116.20
Price / CashN/A57.1640.6337.94
Price / Book-5.745.194.754.71
Net Income-$12.56M$151.85M$118.34M$225.20M
7 Day Performance-3.73%-5.29%11.78%-2.58%
1 Month PerformanceN/A-4.63%9.77%3.57%
1 Year PerformanceN/A9.45%29.99%16.54%

BioHarvest Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BHST
BioHarvest Sciences
N/A$6.20
+0.2%
$13.00
+109.7%
N/A$101.84M$22.43M-4.96N/AAnalyst Forecast
News Coverage
High Trading Volume
GHRS
GH Research
1.8822 of 5 stars
$7.70
-0.4%
$35.67
+363.2%
+40.7%$400.63MN/A0.0010Positive News
AKBA
Akebia Therapeutics
3.4855 of 5 stars
$1.83
+0.5%
$7.50
+309.8%
+53.0%$399.27M$194.62M0.00167
ESPR
Esperion Therapeutics
3.9012 of 5 stars
$2.02
-20.8%
$8.17
+304.3%
+2.4%$398.02M$116.33M-3.13240Analyst Forecast
Gap Down
High Trading Volume
LRMR
Larimar Therapeutics
1.9228 of 5 stars
$6.20
+1.5%
$20.43
+229.5%
+0.7%$395.62MN/A-5.3130Analyst Forecast
CYRX
Cryoport
3.1206 of 5 stars
$7.57
-3.4%
$12.50
+65.1%
-49.9%$374.19M$233.26M0.001,170Short Interest ↓
Positive News
OLMA
Olema Pharmaceuticals
1.8955 of 5 stars
$6.30
-6.3%
$27.00
+328.6%
-55.1%$360.99MN/A-2.8880Insider Trade
Gap Up
SAGE
Sage Therapeutics
4.1579 of 5 stars
$5.57
-1.8%
$12.35
+121.8%
-76.2%$340.72M$86.46M0.00690Analyst Forecast
CTNM
Contineum Therapeutics
1.4626 of 5 stars
$13.20
-4.3%
$29.25
+121.6%
N/A$340.30M$50M0.0031News Coverage
KMDA
Kamada
3.9043 of 5 stars
$5.82
+0.5%
$14.50
+149.1%
-3.2%$334.53M$142.52M20.68360Positive News
AQST
Aquestive Therapeutics
1.447 of 5 stars
$3.65
-1.1%
$9.80
+168.5%
+80.2%$332.81M$50.58M0.00160Analyst Forecast
Analyst Revision
News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:BHST) was last updated on 12/19/2024 by MarketBeat.com Staff
From Our Partners